I read with interest the Viewpoint by Dennis McGonagle and colleagues,[@bib1] in which they associate the changes that occur in the lungs of patients with COVID-19 with macrophage activation syndrome (MAS) and emphasise the possible occurrence of pre-terminal disseminated intravascular coagulation.

Coagulation disorders in patients with COVID-19 were initially thought to be due to systemic disseminated intravascular coagulopathy but evidence from autopsies instead shows that these disorders are due to a procoagulant event together with a severe inflammatory state.[@bib2]

Serum ferritin is elevated in 71% of patients with catastrophic antiphospholipid antibody syndrome. Indeed, four well recognised clinical conditions exist that might be associated with high ferritin concentrations: MAS, adult-onset Still\'s disease, catastrophic antiphospholipid antibody syndrome, and septic shock.[@bib3]

Adult-onset Still\'s disease has diagnostic criteria that do not correspond to the clinical presentation and disease course of critically ill patients with COVID-19. MAS is closely related to juvenile idiopathic arthritis, although it has been described in other autoimmune diseases such as lupus, and is seen more frequently among children and adolescents than in adults. Bleeding, however, occurs more frequently in MAS than thrombosis does.[@bib3], [@bib4]

Antiphospholipid antibodies have been reported in some patients with COVID-19, and one study found a high concentration of lupus anticoagulant antibody in 50 (88%) of 57 tested individuals.[@bib5] When reviewing the diagnostic criteria, causes, and clinical forms of catastrophic antiphospholipid antibody syndrome, and the autopsy findings from patients with COVID-19, this syndrome is very likely to be the cause of exaggerated inflammatory response and thrombosis in most patients with severe COVID-19, even in children with severe multisystemic inflammatory response who have had an initial negative test for SARS-CoV-2. The medical community must address this diagnostic possibility since it could radically change the treatment and prognosis of critically ill patients with COVID-19.
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